SCODiA Report by MLBI Lab

Single-Cell Transcriptomic Insights into Cellular Heterogeneity and Pathological Mechanisms in Familial (E280A) and Sporadic Alzheimer's Disease

This single-cell RNA sequencing analysis of human brain tissue reveals distinct and shared cellular and molecular alterations in familial (E280A) and sporadic Alzheimer's disease (AD) compared to control. Population analysis shows increased reactive glial cells in sporadic AD. Cell-cell interaction studies highlight dysregulated glutamatergic signaling, reduced synaptic adhesion in both AD forms, with sporadic AD exhibiting prominent neuroinflammation and cerebrovascular pathology, while E280A shows signs of oligodendrocyte dysfunction. Neuronal surfaceome analysis identifies markers of healthy function in controls, altered cAMP signaling and serotonergic transmission in E280A neurons, and widespread inflammatory, synaptic, and stress-related markers in sporadic AD neurons. Pathway enrichment analyses (GSA, GSEA) consistently point to neurodegenerative processes, profound synaptic and mitochondrial dysfunction, inflammation, ferroptosis, and cerebrovascular pathology in AD, with notable cell-type-specific responses and a degree of overlap between E280A and sporadic AD at the pathway level.

Contents

  1. Dataset overview
  2. UMAP Visualization of Cell Populations by Condition, Sample, and Cell Type Hierarchies in Alzheimer's Disease Brain
  3. Major Cell Type Scoring and Distribution on UMAP
  4. Marker Expression Dot Plot for Cell Subtype Annotation Assessment
  5. Minor Cell Type Population Analysis Across Alzheimer's Disease Conditions
  6. Cell-Cell Interaction Analysis Across Alzheimer's Disease Conditions
  7. Condition-Specific Cell-Cell Interaction Patterns in Alzheimer's Disease
  8. Neuron Surfaceome Marker Expression Across Alzheimer's Disease Conditions
  9. Gene Ontology (GSA) Analysis of Neurons Across Alzheimer's Disease Conditions
  10. Gene Set Enrichment Analysis Across Brain Cell Types in Alzheimer's Disease
  11. Discussion
  12. Query List

0. Dataset overview

데이터셋 요약

데이터 형식: AnnData 객체 (단일 세포 RNA-seq 데이터에서 파생)

세포 수: 43,743개

유전자 수: 26,318개

종: 인간

조직: 뇌

조건: E280A, Control, Sporadic

임상 및 병리학적 정보

사전 계산된 분석 결과

분석 주의사항

추론된 질병/생물학적 맥락

1. UMAP Visualization of Cell Populations by Condition, Sample, and Cell Type Hierarchies in Alzheimer's Disease Brain

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents five UMAP (Uniform Manifold Approximation and Projection) plots, visualizing the global transcriptional landscape of 43,743 cells from human brain tissue. These plots are colored by different metadata attributes: condition (Control, E280A, Sporadic Alzheimer's Disease), sample (individual patients), celltype_major, celltype_minor, and celltype_subset. The primary goal is to assess the quality of the data embedding, the distinctness of cell type annotations, and the distribution of cells across conditions and samples. This allows for an initial understanding of the dataset's structure and potential batch effects or disease-specific shifts in cell composition or state.

Visual Summary

Condition

The UMAP colored by condition shows a significant degree of overlap between cells from Control, E280A, and Sporadic conditions across most of the major cell clusters. This mixing suggests that the major cell type composition is broadly preserved across conditions, and that any major batch effects related to condition have been mitigated. However, some areas show differential enrichment:

Sample

The sample UMAP displays an excellent mixing of cells from different individual patients across the entire embedding. Cells from each unique sample (represented by distinct colors) are largely intermingled within the larger clusters, rather than forming segregated patient-specific clusters. This indicates successful batch correction and suggests that variability due to individual patient differences or technical artifacts is not dominating the observed biological separation of cell types.

Celltype_major

This UMAP shows clear and robust separation of the major cell types: Astrocyte, Endothelial cell, Microglia, Neuron, Oligodendrocyte, and Stromal cell. Each major cell type forms distinct clusters, demonstrating high confidence in these high-level annotations.

Celltype_minor

The celltype_minor UMAP refines the major cell type annotations, revealing further substructure.

Celltype_subset

The celltype_subset UMAP provides the most granular view of cellular identities, revealing fine-grained subpopulations.

Biological Interpretation

The UMAP visualizations demonstrate a high-quality single-cell RNA-seq dataset from human brain, successfully processed to reveal intricate cellular heterogeneity. The excellent mixing of cells by sample indicates that technical variability and patient-specific batch effects have been largely controlled, allowing for robust biological comparisons.

The clear separation of celltype_major, celltype_minor, and celltype_subset confirms the success of cell type annotation and the ability to resolve diverse cell populations present in the brain. The resolution of glial cell states, particularly Microglia (M0, M1, M2a, M2b, M2c) and Oligodendrocyte lineage cells (Immature, Mature Myelinating, Mature Non-Myelinating, Precursor cell), is particularly valuable in the context of Alzheimer's disease. Microglial activation and oligodendrocyte dysfunction are well-known pathological features of AD, and the ability to distinguish these precise states at a single-cell level will be critical for understanding disease mechanisms. The extensive heterogeneity observed within the neuronal populations is also consistent with the complex functional organization of the brain and provides a basis for investigating subtype-specific vulnerability or responses to AD pathology.

While the condition UMAP shows substantial overlap, indicating shared basic cellular architecture, the subtle enrichments of E280A and Sporadic AD cells in certain regions suggest that disease-specific shifts in cell proportions or the activation of unique cell states are detectable. These subtle differences, rather than gross changes in major cell type presence, are often characteristic of complex neurodegenerative diseases like Alzheimer's. Further differential gene expression and pathway analyses within these specific cell types and subsets will be necessary to pinpoint the precise molecular changes associated with the E280A mutation and sporadic AD.

Annotation Notes

The UMAPs provide strong visual evidence for the high quality and distinctness of the cell type annotations at all hierarchical levels (celltype_major, celltype_minor, celltype_subset). The clustering of cells aligns well with expected biological identities and relationships, supporting the reliability of downstream cell-type-specific analyses. The effective removal of batch effects (as seen in the sample UMAP) further strengthens confidence in the biological signals observed. The resolution of microglial activation states and oligodendrocyte maturation stages is particularly strong, which is highly relevant for brain pathology studies. While neuronal subsets show some intermingling, this is often expected due to their continuous transcriptional states, and the overall distinction of major neuronal clusters is clear.

2. Major Cell Type Scoring and Distribution on UMAP

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis visualizes the distribution of major cell types within the single-cell RNA-seq dataset using a Uniform Manifold Approximation and Projection (UMAP) dimensionality reduction. Specifically, it displays the calculated "HiCAT_major_score" for each major cell type (Endothelial cell, Stromal cell, Microglia, Neuron, Astrocyte, Oligodendrocyte) across the UMAP embedding. These score maps are presented alongside a UMAP plot colored by the definitive celltype_major annotations, allowing for a direct comparison of score-based cell type identification with the pre-assigned cell type labels. This visualization serves to validate the cell type annotation quality and the overall structure of the cellular landscape.

Visual Summary

The UMAP embedding reveals several distinct cell clusters, indicative of diverse cell populations within the brain tissue.

Biological Interpretation

The strong agreement between the HiCAT_major_score heatmaps and the celltype_major categorical assignments confirms the high quality and specificity of the major cell type annotations in this single-cell RNA-seq dataset from human brain tissue.

Annotation Notes

The high congruence between the HiCAT_major_score heatmaps and the celltype_major annotations indicates a robust and reliable cell type assignment for the major populations. This suggests that the initial clustering and subsequent annotation steps were successful in capturing the distinct transcriptional profiles of these diverse cell types in the brain. The clear separation of clusters further supports the quality of the UMAP embedding and the biological distinctiveness of the identified cell populations. No significant ambiguities or mixed populations were evident at the major cell type level, providing a strong basis for further granular analysis.

3. Marker Expression Dot Plot for Cell Subtype Annotation Assessment

Report figure

[Analysis Visualization Results]...

Analysis Overview

This dot plot visualizes the expression of automatically identified marker genes across different celltype_subset populations derived from the single-cell RNA-seq data. The primary objective of this analysis is to evaluate the distinctiveness and biological accuracy of these cell type annotations based on their gene expression profiles. In the plot, the size of each dot correlates with the fraction of cells within a given group that express a particular gene, while the color intensity (red scale) indicates the mean expression level of that gene within the group, normalized between 0 and 1. The markers were identified with a focus on surfaceome genes and specific statistical cutoffs as defined in the find_cfg parameters.

Visual Summary

The dot plot presents a matrix structure where rows represent various celltype_subset populations (e.g., Astrocyte, Microglia (M0), Neuron (Glutamatergic)), and columns correspond to individual marker genes. Overall, many cell type subsets exhibit distinct blocks of highly expressed and specific markers (characterized by large, dark red dots), generally reinforcing their assigned annotations. For example, Astrocytes, Microglia, and the Oligodendrocyte lineage show clear enrichment of expected marker genes. Similarly, GABAergic and Glutamatergic neuronal subtypes display characteristic expression patterns. However, several celltype_subset populations demonstrate unexpected or contradictory marker profiles. Notably, genes shown as markers for "Neuron (Dopaminergic)" are canonical GABAergic markers, and markers for "Neuron (Noradrenergic)" are clearly indicative of oligodendrocytes.

Biological Interpretation

The marker expression dot plot provides important insights into the quality and specificity of celltype_subset annotations across the human brain single-cell RNA-seq dataset.

Well-Supported Cell Type Annotations:

Cell Type Annotation Discrepancies and Areas for Review:

Critical Misassigned Neuronal Markers

Annotation Notes

The marker expression analysis confirms the identity of many cell types and their subsets, validating a substantial portion of the cell type annotations. However, the presence of major discrepancies in marker assignment for "Neuron (Dopaminergic)" and "Neuron (Noradrenergic)" populations raises significant concerns regarding their accuracy. These specific neuronal subsets appear to be misannotated, exhibiting expression profiles characteristic of GABAergic neurons and oligodendrocytes, respectively. The observed overlap in markers among endothelial, fibroblast, and smooth muscle cells also warrants further scrutiny. These findings strongly recommend a comprehensive re-evaluation and potential correction of the annotations for these problematic cell type subsets to ensure the reliability and biological integrity of downstream analyses.

4. Minor Cell Type Population Analysis Across Alzheimer's Disease Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This visualization presents the relative proportions of minor cell types across individual samples for three distinct conditions: Control, E280A (a familial Alzheimer's disease mutation), and Sporadic (sporadic Alzheimer's disease). Each bar represents a single sample, and the colored segments within each bar denote the percentage contribution of different minor cell types to the total cell population within that sample. This analysis allows for a direct comparison of cellular composition changes associated with different forms of Alzheimer's disease.

Visual Summary

The bar plots reveal distinct patterns in cellular composition across the conditions:

Biological Interpretation

The observed shifts in cell type populations are highly relevant to the inferred biological context of Alzheimer's disease:

Clinical or Translational Implications

5. Cell-Cell Interaction Analysis Across Alzheimer's Disease Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates cell-cell interaction (CCI) patterns using CellPhoneDB results derived from single-cell RNA sequencing data of human brain tissue across three conditions: Control, E280A (a familial Alzheimer's disease mutation), and Sporadic (sporadic Alzheimer's disease). The goal is to identify differences in ligand-receptor interactions between various brain cell types under healthy and diseased states, focusing on potential mechanisms underlying Alzheimer's pathology. The results are visualized as dot plots, where the size of the dot represents the negative log10 of the p-value, and the color intensity represents the log2 of the mean expression of the interacting ligand-receptor pair. A maximum of 80 significant interactions are shown per condition group.

Visual Summary

The three dot plots display the most significant cell-cell interaction patterns for Control, E280A, and Sporadic conditions. Each plot's Y-axis lists cell-cell pairs (e.g., "Neuron|Neuron", "Astrocyte|Neuron"), and the X-axis lists specific ligand-receptor gene pairs.

Biological Interpretation

The observed changes in cell-cell interactions provide insights into the molecular mechanisms underlying Alzheimer's disease pathology in the brain.

  1. Dysregulated Glutamatergic Signaling: The consistently strong, and in some cases intensified (higher mean expression), Glutamate_byGLS_and_SLC1A*_GRM* interactions in both E280A and Sporadic conditions point towards a significant perturbation of glutamate homeostasis. Glutamate is the primary excitatory neurotransmitter, and its dysregulation, leading to excitotoxicity, is a well-established mechanism in AD pathogenesis (e.g., excessive activation of metabotropic glutamate receptors, GRMs, or altered transporter function, SLC1A/EAATs). The involvement of GLS (glutaminase), a key enzyme in glutamate synthesis, further underscores altered glutamate metabolism. These interactions primarily occur between neurons, and importantly, between astrocytes and neurons, highlighting the crucial role of astrocytes in modulating neuronal excitability and glutamate clearance PubMed search: "glutamate excitotoxicity Alzheimer's astrocytes".
  2. Synaptic Remodeling and Dysfunction:
  1. Astrocytic Dysfunction and Lipid Metabolism: The "Astrocyte|Astrocyte" interaction involving Cholesterol_byLAL_APOA1 shows decreased intensity in Sporadic AD compared to Control and E280A. Apolipoprotein A1 (APOA1) is involved in cholesterol transport, and dysregulation of cholesterol metabolism is a risk factor for AD. This finding suggests a potential impairment in astrocytic lipid handling or intercellular communication within the astrocyte network in sporadic AD, which could impact amyloid-beta clearance or neuroinflammation PubMed search: "astrocytes cholesterol metabolism Alzheimer's".
  2. Oligodendrocyte and Myelin Involvement: Interactions involving oligodendrocytes and oligodendrocyte progenitor cells (OPCs) with neurons, particularly NRXN-NLGN and CNTN1_NOTCH1, suggest altered neuron-glia communication that could affect myelin integrity or OPC differentiation, both increasingly recognized in AD PubMed search: "oligodendrocyte dysfunction Alzheimer's". The emergence of CNTN1_NOTCH1 (Contactin-1 and Notch1, involved in cell-cell adhesion and differentiation) in "Oligodendrocyte|Neuron" in E280A could signify altered developmental pathways or stress responses.

Clinical or Translational Implications

These findings highlight several potential avenues for therapeutic intervention and biomarker development in Alzheimer's disease:

  1. Targeting Glutamatergic Dysregulation: The consistently strong glutamatergic interactions in AD conditions suggest that modulating specific components of the Glutamate_byGLS_and_SLC1A*_GRM* axis, particularly between neurons and astrocytes, could be a therapeutic strategy. For example, specific GRM subtypes (e.g., GRM3, GRM5) could be targeted to reduce excitotoxicity, or enhancing the function of astrocytic glutamate transporters (SLC1A family) to improve glutamate clearance. This aligns with existing AD treatments like memantine, which targets NMDA receptors (another glutamate receptor type). Further investigation into the specific GRM subtypes and SLC1A transporters involved in these critical interactions is warranted.
  2. Restoring Synaptic Integrity: The changes in PTPRD-SLTRK/LARRP interactions suggest that compounds designed to restore or enhance these specific synaptic adhesion and signaling pathways could potentially mitigate synaptic dysfunction and cognitive deficits in AD. Similarly, understanding the precise remodeling of NRXN-NLGN interactions could reveal targets to stabilize or regenerate synapses.
  3. Astrocytic-Targeted Therapies: The observed alterations in astrocytic cholesterol metabolism via Cholesterol_byLAL_APOA1 interactions in sporadic AD point to astrocytes as potential therapeutic targets for lipid-modulating strategies. Enhancing astrocytic cholesterol efflux or targeting specific lipid transport proteins could be explored to impact AD progression, especially in sporadic forms of the disease.
  4. Biomarker Development: Specific patterns of dysregulated CCI, especially highly significant and condition-specific changes in ligand-receptor pairs, could serve as novel biomarkers for AD diagnosis, prognosis, or monitoring treatment response. For instance, the relative intensity of Glutamate_byGLS_and_SLC1A*_GRM* interactions or the reduction in PTPRD-mediated interactions could be investigated in biofluids or imaging studies.

Experimental Validation:

Further experimental validation could involve:

6. Condition-Specific Cell-Cell Interaction Patterns in Alzheimer's Disease

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis investigates condition-specific cell-cell interaction (CCI) patterns using single-cell RNA sequencing data from human brain tissue. The focus is on interactions among Microglia, Astrocytes, Endothelial cells, Fibroblasts, Oligodendrocytes, and Oligodendrocyte progenitor cells. The aim is to identify CCIs that differ significantly between Control, E280A (familial Alzheimer's disease), and Sporadic (sporadic Alzheimer's disease) conditions, shedding light on potential disease mechanisms and therapeutic targets. The dot plot visualizes the strength (color intensity) and significance (dot size) of these interactions across individual samples for each condition.

Visual Summary

The dot plot reveals distinct and condition-specific patterns of cell-cell interactions:

Biological Interpretation

The differential CCI patterns highlight key pathological processes in Alzheimer's disease:

  1. Impaired Oligodendrocyte Function and Myelination in Familial AD (E280A):
  1. Pronounced Neuroinflammation and Microglial Dysregulation in Sporadic AD:
  1. Extensive Cerebrovascular Pathology and ECM Remodeling in Sporadic AD:

Clinical or Translational Implications

The identified differential cell-cell interactions offer promising avenues for therapeutic intervention in Alzheimer's disease:

  1. Targeting Neuroinflammation in Sporadic AD:
  1. Restoring Cerebrovascular Integrity and Function in Sporadic AD:
  1. Promoting Myelination and Oligodendrocyte Health in Familial AD (E280A):

These findings underscore the diverse molecular mechanisms underlying familial versus sporadic forms of Alzheimer's disease, suggesting the need for tailored therapeutic approaches.

7. Neuron Surfaceome Marker Expression Across Alzheimer's Disease Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents a dot plot illustrating the expression of surfaceome-specific genes in neurons across different conditions related to Alzheimer's disease (Control, E280A, and Sporadic) and individual patient samples. Each dot represents a gene-sample combination, with the size of the dot indicating the fraction of cells within that sample group expressing the gene (non-zero expression), and the color intensity reflecting the mean expression level of the gene in that group. The plot focuses on surfaceome markers, which are particularly relevant for cell-cell communication, interaction with the extracellular matrix, and therapeutic targeting due to their accessibility. The data is derived from single-cell RNA-seq of human brain tissue.

Visual Summary

The dot plot reveals distinct patterns of surfaceome marker expression in neurons, broadly categorized by the Control, E280A (familial AD), and Sporadic (sporadic AD) conditions.

Biological Interpretation

The differential expression of these surfaceome markers in neurons provides insights into the cellular changes occurring in Alzheimer's disease.

Markers Associated with Healthy Neuronal Function (High in Control):

Markers Associated with E280A (Familial AD) Pathophysiology:

Markers Associated with Sporadic AD Pathophysiology (High in Sporadic):

Clinical or Translational Implications

The identified surfaceome markers offer promising avenues for therapeutic intervention and biomarker development in Alzheimer's disease.

Therapeutic Targets:

Further research involving functional validation of these surfaceome markers in neuronal models of AD, as well as their expression patterns in post-mortem human brain tissue and biofluids, would be crucial to confirm their utility as therapeutic targets or biomarkers.

8. Gene Ontology (GSA) Analysis of Neurons Across Alzheimer's Disease Conditions

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Ontology (GSA) results for Neuron cell types from human brain single-cell RNA-seq data. The goal is to identify biological pathways and processes that are significantly enriched (indicating upregulation or increased prominence) in neurons from specific conditions compared to the rest of the dataset. Separate analyses were performed for 'Control', 'E280A' (familial Alzheimer's disease mutation), and 'Sporadic' (sporadic Alzheimer's disease) conditions, each compared against the aggregate of the other conditions present in the dataset. The results are visualized as bar plots, displaying the top enriched terms ranked by their statistical significance (-log(p-val) and -log(q-val)).

Visual Summary

The bar plots display the most significantly enriched Gene Ontology (GO) terms in Neurons for each condition. The length of the bars represents the -log(p-val), and the right panel shows the -log(q-val) (adjusted p-value), both indicating statistical significance.

Overall, the magnitude of enrichment (as indicated by -log(p-val) and -log(q-val)) is considerably higher for Control and E280A conditions compared to Sporadic AD, suggesting more distinct or pervasive pathway changes in the former two groups relative to the aggregated "others" group.

Biological Interpretation

The GSA results for Neurons reveal both shared and distinct biological processes characterizing different Alzheimer's disease (AD) conditions when compared to other groups. The term GSA_up generally implies that the genes associated with these pathways are upregulated or more prominently active in the target condition.

Shared Neurodegenerative Signatures in Control and E280A Neurons:

Distinct Neuronal Pathology in Sporadic AD:

Clinical or Translational Implications

The distinct and shared pathway enrichments in neurons across different AD conditions offer valuable insights for clinical and translational research:

9. Gene Set Enrichment Analysis Across Brain Cell Types in Alzheimer's Disease

Report figure

[Analysis Visualization Results]...

Analysis Overview

This analysis presents Gene Set Enrichment Analysis (GSEA) results visualized as a dot plot. The GSEA compares gene expression profiles for each celltype_minor within three conditions (Control, E280A, and Sporadic Alzheimer's Disease) against the remaining conditions in the dataset ('others'). The plot highlights enriched or depleted biological pathways across different cell types and disease states, providing insights into condition-specific and cell-type-specific molecular alterations. The dot size corresponds to the statistical significance (-log(p-value)), and the color indicates the Normalized Enrichment Score (NES), where red signifies positive enrichment (upregulation) and blue signifies negative enrichment (downregulation).

Visual Summary

The GSEA dot plot reveals distinct patterns of pathway dysregulation across various brain cell types in Alzheimer's disease (AD) conditions (E280A and Sporadic) compared to other conditions, including control.

Metabolic Dysregulation:

Biological Interpretation

The GSEA results strongly corroborate the established multifaceted pathology of Alzheimer's disease, highlighting cell-type-specific vulnerabilities and responses.

  1. Direct AD Pathology: The consistent upregulation of "Alzheimer disease" and "Pathways of neurodegeneration" across multiple neural cell types (neurons, microglia, oligodendrocytes, OPCs) in both E280A and Sporadic AD conditions underscores the broad molecular impact of the disease. The corresponding downregulation in Control cells, relative to the combined disease states, emphasizes these pathways as hallmarks of AD pathology.
  2. Neuroinflammation: The prominent enrichment of "NF-kappa B signaling pathway" and "Chemokine signaling pathway" in microglia, and to some extent in astrocytes and endothelial cells, points to a robust inflammatory and immune response in AD brains. Microglia, as the resident immune cells of the brain, are known to become activated and contribute to chronic inflammation, which is a key driver of neurodegeneration in AD 1. This indicates both protective and detrimental roles of microglia in AD.
  3. Metabolic Dysfunction and Mitochondrial Impairment: The negative enrichment of "Oxidative phosphorylation" in neurons of AD patients is highly significant, suggesting mitochondrial dysfunction and impaired energy metabolism, which are critical events in AD pathogenesis leading to neuronal vulnerability and death 2. The dysregulation of "AMPK signaling pathway" further supports altered cellular energy homeostasis. The increased activity of "Cholesterol metabolism" in microglia and astrocytes points to their active roles in lipid processing and inflammation, which are closely linked to amyloid-beta clearance and deposition in AD 3.
  4. Synaptic Loss and Dysfunction: The widespread negative enrichment of pathways related to "Glutamatergic synapse," "Cholinergic synapse," and "Neuroactive ligand-receptor interaction" in neurons in both AD conditions is a direct molecular signature of synaptic dysfunction and loss, which correlates strongly with cognitive decline in AD.
  5. Programmed Cell Death and Stress Responses: The strong positive enrichment of "Ferroptosis" in neurons and oligodendrocytes in AD conditions suggests that this specific form of iron-dependent cell death may be a significant contributor to neuronal and white matter loss in AD. Evidence for ferroptosis in AD is emerging 4. Upregulation of "Protein processing in endoplasmic reticulum" in astrocytes and microglia indicates ER stress, another crucial component of cellular pathology in neurodegenerative diseases.
  6. Vascular Contributions: The enrichment of "Fluid shear stress and atherosclerosis" in endothelial cells highlights the involvement of vascular dysfunction in AD, supporting the concept of AD as a multi-factorial disease with significant cerebrovascular components 5.

Clinical or Translational Implications

These GSEA results provide crucial insights for understanding AD pathogenesis and identifying potential therapeutic targets.

The striking similarities between E280A and Sporadic AD at the pathway level suggest that many therapeutic strategies might be broadly applicable across different AD etiologies, although specific nuances between the conditions warrant further investigation.

References:

  1. Neuroinflammation in AD: PubMed Search (e.g., Block, L. M., & Lipton, A. M. (2021). Microglia-driven neuroinflammation in Alzheimer's disease.)
  2. Mitochondrial dysfunction in AD: PubMed Search (e.g., Reddy, P. H. (2022). Mitochondrial Dysfunction and Oxidative Stress in Alzheimer's Disease: A Target for Disease-Modifying Therapies.)
  3. Cholesterol metabolism in AD: PubMed Search (e.g., Liu, Y. et al. (2022). Roles of Cholesterol Metabolism in Alzheimer's Disease.)
  4. Ferroptosis in AD: PubMed Search (e.g., Hambright, W. S. et al. (2021). Ferroptosis and Neurodegeneration: The Elephant in the Room.)
  5. Cerebrovascular dysfunction in AD: PubMed Search (e.g., Sweeney, M. D. et al. (2021). Cerebrovascular Dysfunction in Alzheimer's Disease.)

10. Discussion

This single-cell transcriptomic analysis provides a comprehensive view of cellular and molecular alterations in human brain tissue affected by familial (E280A) and sporadic Alzheimer's disease (AD). The initial UMAP and population analyses confirm robust cell type identification and reveal a notable increase in reactive Astrocytes and Microglia specifically in Sporadic AD samples, suggesting pronounced neuroinflammation and gliosis compared to the more subtle changes observed in E280A and control groups.

Cell-cell interaction (CCI) analyses unveil critical shifts in intercellular communication. Both E280A and Sporadic AD conditions demonstrate dysregulated glutamatergic signaling, primarily involving neurons and astrocytes (e.g., Glutamate_byGLS_and_SLC1A*-GRM*), and altered synaptic adhesion molecules (e.g., PTPRD-SLTRK/LARRP). A key distinction emerges in familial AD (E280A), which shows attenuated oligodendrocyte-related interactions (e.g., PDGFA-PDGFRA, BMP7-BMPR1A), indicating potential impairment in myelination or repair mechanisms. In stark contrast, Sporadic AD exhibits a dramatic upregulation of CCIs related to neuroinflammation (e.g., SPP1-CD44, TREM2-TYROBP/APOE in microglia) and extensive cerebrovascular pathology (e.g., VEGFA-KDR, NOTCH, Collagen-Integrin interactions in endothelial cells). These findings highlight more widespread immune and vascular alterations in sporadic AD compared to the familial form.

Neuronal surfaceome marker analysis further differentiates the conditions. While Control neurons maintain markers for healthy function (ITM2C, NRN1), E280A neurons show upregulation of ADCY9 and HTR1E, implying altered cAMP signaling and serotonergic transmission. Sporadic AD neurons exhibit a broad upregulation of genes associated with inflammation (SPP1, ITGAV), altered synaptic function (EPHB2, CACNA1I, GRIK4, GRIK5), and stress responses (RTN4RL1). This reinforces the concept of neurons being actively involved in the disease pathology, not merely passive victims, with distinct responses depending on the AD subtype.

Gene Ontology (GSA) and Gene Set Enrichment Analysis (GSEA) consistently reveal shared core pathological pathways alongside condition-specific alterations. Broad neurodegenerative pathways, protein processing, and oxidative phosphorylation are highly enriched in neurons from both Control and E280A (compared to 'others'), which could reflect early disease vulnerability, compensatory mechanisms, or the subtle impact of these conditions compared to a more severely impacted 'others' group. In Sporadic AD neurons, GSA highlights axon guidance, glutamatergic synapse, and cell adhesion pathways. GSEA across all cell types underscores pervasive synaptic and mitochondrial dysfunction in neurons (downregulation of 'Glutamatergic synapse', 'Oxidative phosphorylation'), robust neuroinflammation in microglia (upregulation of 'NF-kappa B signaling pathway', 'Chemokine signaling pathway'), and significant ferroptosis in neurons and oligodendrocytes in both E280A and Sporadic AD. Furthermore, vascular dysfunction (e.g., 'Fluid shear stress and atherosclerosis') is evident in endothelial cells from both AD conditions.

Collectively, these results highlight the molecular heterogeneity between familial and sporadic AD, emphasizing that while both forms share core neurodegenerative processes like synaptic and metabolic dysfunction, Sporadic AD presents with more pronounced neuroinflammation and cerebrovascular pathology. Familial E280A AD, conversely, shows earlier indications of oligodendrocyte dysfunction and specific neuronal signaling changes. This multi-omics perspective provides a granular understanding of the cell-type-specific contributions to AD pathogenesis, underscoring the potential for tailored therapeutic strategies.

Hypotheses:

  1. The familial E280A mutation in Alzheimer's disease leads to early and specific dysfunction of oligodendrocyte progenitor cells and oligodendrocytes, manifesting as attenuated cell-cell interactions crucial for myelination and repair (e.g., PDGFA-PDGFRA, BMP7-BMPR1A), which contributes to white matter pathology distinct from sporadic forms.
  2. Sporadic Alzheimer's disease is characterized by a pronounced and widespread neuroinflammatory response, driven by activated microglia (involving SPP1-CD44 and TREM2-TYROBP/APOE pathways) and extensive cerebrovascular pathology (marked by dysregulated VEGFA-KDR, NOTCH, and Collagen-Integrin interactions in endothelial cells), which are more severe than in familial AD.
  3. Neurons in E280A Alzheimer's disease exhibit specific alterations in cAMP signaling (via ADCY9 upregulation) and serotonergic neurotransmission (via HTR1E upregulation), contributing to distinct patterns of synaptic plasticity and cognitive impairment compared to sporadic AD.
  4. Neurons in sporadic Alzheimer's disease actively participate in inflammatory processes (upregulation of SPP1, ITGAV), undergo specific synaptic remodeling (EPHB2, GRIK4, GRIK5), and experience calcium dysregulation (CACNA1I), driving neuronal dysfunction and contributing to disease progression.
  5. Ferroptosis is a significant and actively engaged form of programmed cell death in both neurons and oligodendrocytes in both familial (E280A) and sporadic Alzheimer's disease, contributing to neurodegeneration and myelin loss.

Potential therapeutic targets:

  1. Dysregulated Glutamatergic Signaling (e.g., GRMs, SLC1A family): Dysregulated glutamate homeostasis leading to excitotoxicity is a central and well-established mechanism in AD pathogenesis, particularly impacting neuronal and astrocytic function. Evidence: Consistently strong and often intensified Glutamate_byGLS_and_SLC1A*_GRM* interactions were identified between neurons and astrocytes in both familial (E280A) and sporadic AD conditions through cell-cell interaction analysis. Validation: In vitro assays using specific GRM modulators (agonists/antagonists) or SLC1A transporter enhancers to assess changes in neuronal excitability, synaptic plasticity, and glutamate clearance. In vivo testing in AD animal models to evaluate impact on cognitive function and neurodegeneration.
  2. Microglial Neuroinflammation Pathways (e.g., TREM2-TYROBP/APOE, SPP1-CD44): The upregulation of these microglial pathways in sporadic AD drives detrimental neuroinflammation, modulates microglial function, and impacts amyloid clearance and tissue damage, contributing to disease progression. Evidence: Elevated SPP1-CD44 (Microglia-Microglia/Astrocyte) and TREM2-TYROBP/APOE (Microglia-Microglia/Astrocyte) interactions were prominent in Sporadic AD samples. GSEA results showed significant upregulation of NF-kappa B and chemokine signaling pathways in microglia in AD conditions. Validation: Development and testing of small molecule modulators or antibodies targeting TREM2 (agonists/antagonists) or inhibitors for SPP1/CD44; evaluating these agents in AD animal models to assess their impact on neuroinflammation, amyloid plaque burden, and cognitive outcomes.
  3. Cerebrovascular Integrity (e.g., VEGFA-KDR, NOTCH, Collagen-Integrin pathways) in Endothelial Cells: Extensive cerebrovascular pathology in sporadic AD contributes significantly to blood-brain barrier dysfunction, neuroinflammation, and overall brain dysfunction, making vascular health a critical therapeutic target. Evidence: Widespread increase in Endothelial cell-mediated interactions, including VEGFA-KDR, NOTCH family members, and various Collagen-Integrin complexes, was observed in Sporadic AD through cell-cell interaction analysis. GSEA also showed enrichment of 'Fluid shear stress and atherosclerosis' in endothelial cells in AD. Validation: Strategies aimed at stabilizing the blood-brain barrier (BBB), modulating pathological angiogenesis (e.g., specific VEGF or Notch inhibitors), or reducing extracellular matrix (ECM) stiffening could be explored in AD models. Assessment of BBB permeability, cerebral blood flow, and neuroinflammatory markers would be key.
  4. Oligodendrocyte Differentiation and Myelination (e.g., PDGF-A, BMP7 signaling): Impaired oligodendrocyte progenitor cell (OPC) proliferation, differentiation, and overall oligodendrocyte maturation or repair is suggested as an early feature in familial AD, contributing to white matter pathology. Evidence: Consistent reduction in interactions like PDGFA-PDGFRA and BMP7-BMPR1A involving OPCs and oligodendrocytes was observed in E280A samples through cell-cell interaction analysis. Validation: Administration of growth factors (e.g., PDGF-A) or small molecules known to promote OPC proliferation and differentiation in familial AD models (e.g., PSEN1 mutation models). Assessment of myelin integrity, white matter pathology, and functional recovery.
  5. Ferroptosis Pathway in Neurons and Oligodendrocytes: Ferroptosis, an iron-dependent form of programmed cell death, is strongly implicated as a significant contributor to neuronal and oligodendrocyte loss in both familial and sporadic forms of AD. Evidence: Gene Set Enrichment Analysis (GSEA) showed strong positive enrichment of 'Ferroptosis' in Neurons and Oligodendrocytes in both E280A and Sporadic AD conditions. Validation: Testing specific ferroptosis inhibitors (e.g., ferrostatin-1, liproxstatin-1) in in vitro neuronal/oligodendrocyte models exposed to AD stressors and in vivo AD animal models. Assessment of neuronal survival, myelin integrity, and cognitive function.
  6. Neuronal EPHB2 Receptor: EPHB2 is a receptor tyrosine kinase crucial for synaptic plasticity, and its dysfunction is linked to amyloid-beta (Aβ) toxicity and impaired cognition in AD. Modulating its activity could restore synaptic integrity. Evidence: Upregulation of EPHB2 was observed in Sporadic AD neurons in the surfaceome marker expression analysis. Validation: Development of small molecules or antibodies that stabilize or activate EPHB2 function. Testing these in neuronal culture models to counteract Aβ-induced synaptic dysfunction and in AD animal models to assess improvements in synaptic density and cognitive performance.
  7. ADCY9 and HTR1E in E280A Neurons: Altered cAMP signaling (via ADCY9) and serotonergic neurotransmission (via HTR1E) represent specific dysfunctional pathways in familial AD neurons that could contribute to distinct patterns of synaptic dysfunction and cognitive impairment. Evidence: Elevated expression of ADCY9 (Adenylyl Cyclase 9) and HTR1E (5-hydroxytryptamine receptor 1E) was specifically observed in E280A neurons in the surfaceome marker expression analysis. Validation: Selective modulators of ADCY9 activity or HTR1E agonists/antagonists could be tested in neuronal models derived from familial AD patients to assess their impact on synaptic function, neuronal excitability, and related cognitive processes.

Follow-up validation ideas:

  1. In vitro Co-culture Models: Recreate specific cell-cell pairs (e.g., neuron-astrocyte, neuron-oligodendrocyte, microglia-endothelial cell) and perturb identified ligand-receptor interactions (e.g., using neutralizing antibodies, receptor agonists/antagonists, or genetic knockdown/overexpression). Assess functional consequences such as neuronal excitability, synaptic plasticity, glial activation, blood-brain barrier integrity, or myelination in response to AD-relevant stimuli.
  2. In vivo Animal Models of AD: Confirm the identified cell-cell interaction changes, surfaceome marker expression, and pathway dysregulations in relevant Alzheimer's disease mouse or primate models using techniques like spatial transcriptomics, multiplexed imaging, or proteomics. Subsequently, test the therapeutic potential of targeting key identified ligand-receptor pairs or specific molecular pathways (e.g., ferroptosis inhibitors, specific GPCR modulators) on AD pathology, cognitive outcomes, and cell-type-specific functions.
  3. Human Post-mortem Tissue Analysis: Validate altered expression and localization of key ligand-receptor pairs, surfaceome markers, and pathway components (e.g., ADCY9, SPP1, EPHB2, components of ferroptosis pathways) in human post-mortem AD patient brains (familial and sporadic) using immunohistochemistry, immunofluorescence, RNAscope, or spatial proteomics/transcriptomics to confirm findings in a relevant human context.
  4. Biofluid and Imaging Biomarkers: Investigate if the identified differential expression of surfaceome markers (e.g., SPP1, ITGAV, CACNA1I, EPHB2) or molecular changes in key pathways are detectable in biofluids (CSF, plasma) or through advanced neuroimaging techniques (e.g., PET ligands targeting specific receptors) as potential diagnostic, prognostic, or treatment response biomarkers for different AD subtypes.
  5. Functional Validation of Neuronal Markers: Conduct functional studies (e.g., electrophysiology, calcium imaging, synaptic biochemistry, amyloid processing assays) in iPSC-derived neurons from AD patients (E280A and sporadic) to directly assess the impact of altered ADCY9, HTR1E, EPHB2, CACNA1I expression on neuronal excitability, synaptic function, and overall health.

Limitations:

The analysis is subject to several limitations. First, the marker expression analysis (Section 3) identified significant misannotations for 'Neuron (Dopaminergic)' and 'Neuron (Noradrenergic)' subsets, and substantial marker overlap among endothelial, fibroblast, and smooth muscle cells. These discrepancies necessitate re-evaluation and potential correction of these specific cell type annotations, which could impact the interpretation of findings related to these populations. Second, the Gene Ontology (GSA) results for 'Control_vs_others' neurons showed high enrichment for broad neurodegenerative pathways. While this could reflect subtle early pathology or compensatory mechanisms, it requires careful interpretation and further validation, as the 'others' group might represent more severely impaired states. Third, the study provides a cross-sectional view of transcriptomic changes; it does not capture the dynamic, temporal progression of Alzheimer's disease. Fourth, the analyses focus on gene expression, which may not always directly correlate with protein levels, post-translational modifications, or functional activity of cells and pathways. Finally, while the conditions (Control, E280A, Sporadic) are defined, the specific stage or severity of Alzheimer's disease for each sample within these broad categories is not fully resolved, potentially contributing to observed heterogeneity.

11. Query List

  1. Show and save UMAPs for condition, sample, major cell type, minor cell type, and celltype_subset in two columns.
  2. Show major cell type scores on UMAP and save the result.
  3. Show and save a marker expression dot plot for celltype_subset. SET target_cell = None and var_group_rotation = 45. Leave all other arguments at their default values.
  4. Show and save a population bar plot of minor cell types.
  5. Show and save cell-cell interaction patterns. Select at most 80 cell-cell interactions per group.
  6. Find cell-cell interactions involving Microglia, Astrocyte, Endothelial cell, Fibroblast, Oligodendrocyte, Oligodendrocyte progenitor cell, and Smooth muscle cell that differ significantly between conditions, show them as a dot plot, and save the result. Set max_n_items_per_group to 60. For each interaction identified under each condition, using the provided dataset context, describe the associated signaling pathways and mechanisms and, where relevant, its potential as a therapeutic target and related therapeutic agents.
  7. Show marker expression for Neuron in a dot plot, and save the result. Use only surfaceome markers, with at most 50 markers per condition. For each marker identified under each condition, using the provided dataset context, describe the associated signaling pathways and biological mechanisms within the tissue and, where relevant, its potential as a therapeutic target for the disease and related therapeutic agents.
  8. Show Gene Ontology (GSA) analysis results for Neuron as a bar plot, and save the result.
  9. Show Gene Set Enrichment Analysis results as a dot plot, and save it. Set the color map to RdBu_r, n_pws_to_show to 120, and target_cells to None.
↑ Top